Folgen
-
Host: Jennifer Caudle, DO
Guest: Samuel R. Wilson, MD
Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine.
References:
Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/. Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7. CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/.Agios Pharmaceuticals, Inc. © 2024
All right reserved.
SCD-US-0095 / June 2024 -
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jessie Hsieh, MD
Guest: David Isaacson, MD
About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this gap and potentially improve outcomes by screening for more cancer types. Joining Dr. Charles Turck to share their experiences with MCED testing and a real-world patient case are Drs. Jesse Hsieh and David Isaacson. Dr. Hsieh is the Chairman of the Board of Beacon Health System in Indiana, and Dr. Isaacson is an Assistant Professor of Otolaryngology at the Indiana University School of Medicine.
Reference:
Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at:
http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/cancer-facts-and-figures-2022.pdf. Data on file GA-2021-0065 -
Fehlende Folgen?
-
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Leigh Anne Cantrell, MD, MSPH
The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology.
COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 07/24 -
Host: Matt Birnholz, MD
Guest: Kay Matthews, LCHW
Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis.
Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.
Sage Therapeutics, Inc. All rights reserved.
Sage Therapeutics ©2024 MRC-PPD-00792 06/2024 -
Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc
Guest: Dru Riddle, PhD, DNP, CRNA
When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an antiemetic should be administered from a different class from what's given for prevention.1 Barhemsys® (amisulpride) is an FDA-approved antiemetic for the treatment of PONV in patients who have or have not received prophylaxis.2 Learn more about this treatment option along with current management guidelines, key clinical considerations, and a real-world case study with TJ Gan, MD, MBA, MHS, and Dru Riddle, PhD, DNP. Dr. Gan is the Head of the Division of Anesthesiology and Perioperative Medicine, Critical Care, and Pain Medicine at the University of Texas MD Anderson Cancer Center in Houston, and Dr. Riddle is a certified nurse anesthetist at Texas Christian University in Ft. Worth, TX.
-
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024 -
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
-
Host: Jennifer Caudle, DO
Guest: Tamera A. Paczos, MD, FACOG, FACP
The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories.
COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 02/23 -
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William F.C. Rigby, MD
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-US-2403256 v1.0 - P
Expiration Date 04/16/2025 -
Guest: Adam Narloch
Guest: Michelle Hermiston, MD, PhD
Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH!
© 2024 Sobi, Inc. All Rights Reserved. NP-34329 04/24
-
Host: Richard Lafayette, MD, FACP
Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
-
Guest: Dena Goffman, MD
Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a new, ingenious hemorrhage tool and embraced simulations to train and improve the skills of healthcare professionals throughout the labor and delivery process. Join health and science journalist Catherine Price as she speaks with Dr. Dena Goffman, Vice Chair for Quality and Patient Safety and the Associate Chief and Quality Officer for Obstetrics for NewYork-Presbyterian, about how her work has helped establish goals and quality standards for safer labor and delivery.
© 2024 NewYork-Presbyterian
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France.
TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24 -
Guest: Pierre Elias, MD
In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose patients before symptoms occur. Join health and science journalist Catherine Price as she speaks with Dr. Pierre Elias, Medical Director of Artificial Intelligence at NewYork-Presbyterian, about the future of technology in medicine.
© 2024 NewYork-Presbyterian
-
Guest: Michael Kaplitt, MD, PhD
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
© 2024 NewYork-Presbyterian
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamie Koprivnikar, MD
Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.
REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24 -
Guest: Stephen I. Pelton, MD
Influenza disproportionately affects adults 65 and older as a result of increased frequency of comorbidities and immunosenescence.1,2 It is also linked to neurologic, cardiovascular, and respiratory complications in high-risk groups, while potentially exacerbating underlying chronic medical conditions.1,2 So how can adjuvanted vaccines help patients who are affected? Dive in to learn more with Dr. Stephen Pelton, Professor of Pediatrics at Boston University Chobanian and Avedisian School of Medicine.
References:
Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA. Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023; 11(10):1525. https://doi.org/10.3390/vaccines11101525USA-FLUD-24-0039 08/24
-
Host: Jennifer Caudle, DO
Guest: Victoria A. Statler, MD, MSc
Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children’s Hospital.
Reference:
Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain.USA-FCV-24-0055 08/24
-
Guess what? The CDC's Advisory Committee on Immunization Practices had a unanimous vote in favor of a preferential recommendation of vaccines for the cool adults who are 65 and older—one of these options is adjuvanted influenza vaccines.1 Talk about a milestone in the world of public health! Now the burning question is why on earth did they decide on adjuvant vaccines? Let's unravel this immunization mystery together, shall we?
Reference:
Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1USA-CRP-23-0037 12/23
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Wendy Wright, DNP
Guest: Elias Chahine, PharmD, FCCP, FASCP
While the flu may seem benign to some, it may result in up to 710,000 hospitalizations and up to 52,000 deaths every year.1 So how are current and concerning trends in declining flu vaccinations being addressed? To hear the latest updates and recommendations, join Dr. Charles Turck as he speaks with Dr. Wendy Wright, Owner and Family Nurse Practitioner at Wright & Associates Family Healthcare in New Hampshire, and Dr. Elias Chahine, Professor of Pharmacy Practice at Palm Beach Atlantic University in West Palm Beach, Florida and Clinical Pharmacy Specialist at Wellington Regional Medical Center.
Reference:
Disease Burden of Influenza. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/about/burden/index.html. Updated October 4, 2022. Accessed November 28, 2023.USA-CRP-23-0043 01/24
- Mehr anzeigen
